Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Had received two-dose priming vaccination in previous phase I trial~* Be able to show legal identity card for the sake of recruitment~* Be able to understand and sign the informed consent.~Exclusion Criteria:~* Woman： Who breast-feeding or planning to become pregnant during the study~* Any history of allergic reactions to vaccines or eggs~* Autoimmune disease or immunodeficiency~* Diabetes mellitus (type I or II), with the exception of gestational diabetes~* Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years~* Hypertension that was not well controlled by medication or is more than 145/95 mmHg at enrollment~* Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study~* Guillain-Barre Syndrome~* Women subjects with positive urinary pregnancy test~* Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months~* History of any blood products administration within 3 months before the dosing~* Administration of any other investigational research agents within 30 days before the dosing~* Administration of any live attenuated vaccine within 30 days before the dosing~* Administration of subunit or inactivated vaccines, e.g. pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing~* Be receiving anti-TB prophylaxis or therapy currently~* Axillary temperature \>37.0 centigrade at the time of dosing~* Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment~* Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 61 Years
- Healthy Volunteers: t

Study Arms:
- No.1: 1.25 ug (Type: EXPERIMENTAL): None
- No.2: 2.5 ug (Type: EXPERIMENTAL): None
- No.3: 5.0 ug (Type: EXPERIMENTAL): None
- No. 4: 10 ug (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).